Skip to main content

$1.23 -0.02 (-1.21%)

High

$1.29

Low

$1.18

Trades

155

Turnover

$303,224

Volume

249,053
30 June 2023 at 4:10pm
Register to track RAC and receive email alerts.
Subject
RAC Ann: Race investor briefing invitation

RAC Ann: Quarterly Activity Report & Appendix 4C

RAC Ann: Zantrene Protects Mouse Hearts from Chemotherapy Damage

RAC Ann: Zantrene shows synergy with kinase inhibitors in melanoma

RAC Ann: Zantrene Improves Immune Therapy Treatment of Melanoma

RAC Ann: Zantrene data published in Cancer Research Journal

RAC Ann: Notification of buy-back - RAC

RAC Ann: Race Oncology Announces On-Market Share Buyback

RAC Ann: EMD AML MDS Trial Expands to Europe

RAC Ann: Zantrene AML trial in Israel advances to Phase 2

RAC Ann: Trading Halt

RAC Ann: Pause in Trading

RAC Ann: Dr Guy Breitenbucher joins Race SAB

RAC Ann: Appendix 3Y - Mary Harney

RAC Ann: Appendix 3Y - Dr Daniel Tillett

RAC Ann: Appendix 3Y - Phillip Lynch

RAC Ann: Appendix 3Y - Dr John Cullity

RAC Ann: Notification of cessation of securities - RAC

RAC Ann: Race Receives Governance Approval for AML EMD & MDS Trial

RAC Ann: Quarterly Activity Report & Appendix 4C

RAC Ann: CEO & CSO Employment Update

RAC Ann: Becoming a substantial holder

RAC Ann: Race receives Human Ethics AML Trial Approval

RAC Ann: Preclinical & Clinical Programs Update

RAC Ann: Supply Agreement for EMD AML Trial

RAC Ann: Zantrene highly effective in EMD AML Mouse Model

RAC Ann: Race ASX Small and Mid-Cap Conference Presentation

RAC Ann: Compelling Zantrene Preclinical Kidney Cancer Data

RAC Ann: Cleansing Notice

RAC Ann: Application for quotation of securities - RAC

RAC Ann: Appendix 3Y - Dr Daniel Tillett

RAC Ann: Appendix 4D & Half-Year Financial Statements

RAC Ann: MD Anderson Preclinical AML Study on Zantrene Published

RAC Ann: Appointment of Chief Financial Officer

RAC Ann: Quarterly Activity Report & Appendix 4C

RAC Ann: Race Receives FY2021 $708k R&D Tax Refund

RAC Ann: Appendix 3Y - Dr John Cullity

RAC Ann: Ceasing to be a substantial holder

RAC Ann: Ceasing to be a substantial holder

RAC Ann: Change in substantial holding

RAC Ann: Appendix 3Y - Dr Daniel Tillett

RAC Ann: Appendix 3Y - Mary Harney

RAC Ann: Appendix 3Y - Phillip Lynch

RAC Ann: Application for quotation of securities - RAC

RAC Ann: Race raises $29.7 million in oversubscribed SPP

RAC Ann: Change of Registry Address

RAC Ann: Appendix 3Y - Dr Daniel Tillett

RAC Ann: SPP Closing Deadline Reminder & Investor Briefing Recording

RAC Ann: Appendix 3Y - Dr Daniel Tillett

RAC Ann: Uni of Newcastle Heart Protection Collaboration Extended

Register to track RAC and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
TLX